President rejects mercy pleas: 3 to hang for mass murders, 1 for rape

New Delhi, May 31: The fourth phase of the coronavirus-triggered lockdown, which began on May 18, saw 85,974 COVID-19 cases till 8 am on Sunday, which is nearly half of the total cases reported in the country so far.

Lockdown 4.0, which will end on May 31 midnight, has accounted for 47.20 per cent of the total coronavirus infection cases, number crunching from the Union Health Ministry data reveals.

The lockdown, which was first clamped on March 25 and spanned for 21 days, had registered 10,877 cases, while the second phase of the curbs that began on April 15 and stretched for 19 days till May 3, saw 31,094 cases.

The third phase of the lockdown that was in effect for 14 days ending on May 17, recorded 53,636 cases till 8 am of May 18.

The country had registered 512 coronavirus infection cases till March 24.

India is the ninth worst-hit nation by the COVID-19 pandemic as of now.        

The first case of COVID-19 in India was reported on January 30 from Kerala after a medical student of Wuhan university, who had returned to India, tested  positive for the virus.

India registered its highest single-day spike of COVID-19 cases on Sunday, with 8,380 new infections reported in the last 24 hours, taking the country's tally to 1,82,143, while the death toll rose to 5,164, according to the Union Health Ministry.

The number of active COVID-19 cases stood to 89,995, while 86,983 people have recovered and one patient has migrated, it said.

"Thus, around 47.75 per cent patients have recovered so far," a senior Health Ministry official said.

With the fourth phase of lockdown ending on Sunday, the Home Ministry on Saturday said 'Unlock-1' will be initiated in the country from June 8 under which the nationwide lockdown will be relaxed to a great extent, including opening of shopping malls, restaurants and religious places, even as strict restrictions will remain in place till June 30 in the country's worst-hit areas.

While announcing the extension of the lockdown in containment zones across the country, the Home Ministry said temples, mosques, churches and other religious places and shopping malls will be allowed to open in a phased manner from June 8, while a decision on opening of schools and colleges will be taken in July in consultation with states.

Ahmedabad, Jan 12: Union Home Minister Amit Shah on Saturday unveiled over 5.5 lakh postcards written by Ahmedabad residents to Prime Minister Narendra Modi, thanking him for the Citizenship (Amendment) Act.

The postcards were stacked on the dais as Shah addressed a gathering of BJP workers who formed letters `C A A’ in front of him.

The state BJP claimed that the party’s “largest awareness campaign” in support of the CAA had found a place in Limca Book of Records and World Record of India.

“It is not just words but a letter of thanks written from the heart. Our public outreach programme is a reply to the lies being spread against the CAA,” Shah said addressing BJP workers from his former Assembly constituency Naranpura.

The BJP had promised to enact the CAA in its manifesto, he said, asking why the Congress did not oppose it then.

Targeting Rajasthan Chief Minister Ashok Gehlot, Shah said, “Congress has a government in Rajasthan. The Congress party in that state had promised that Hindus and Sikhs from Pakistan would be given citizenship.

“Why do you oppose it when we fulfill the promise made by you?” the Union home minister asked.

“In 2006 and 2009, Ashok Gehlot wrote a letter for the same. We covered Hindus, Sikhs, Parsis, Christians, all of them under the Act, you had only mentioned Hindus and Sikhs,” Shah claimed.

Saying that Prime Minister Narendra Modi, by bringing in the CAA, granted “human rights to lakhs of people”, he asked why opposition was against it.

He challenged “Rahul Baba” (Congress leader Rahul Gandhi), Mamata Banerjee and Arvind Kejriwal to show if any provision of the CAA took away the citizenship of Indian Muslims.

“There is no such provision. Lakhs and crores of people have come to India from Pakistan, Bangladesh to save their religion, their self-respect, to save themselves. Where else will they go?” he asked.

“From the first prime minister of the country Jawaharlal Nehru to the first home minister, first president of the country, and Mahatma Gandhi himself had said that whoever comes to India from Pakistan will be granted citizenship. Hindus, Sikhs, Buddhists and Jains coming from Pakistan have nowhere else to go,” he said.

Hyderabad, Jun 30: Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

The Drug Controller General of India - CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020.

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech.

The indigenous, inactivated vaccine developed and manufactured in the company's Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad.

Announcing the vaccine development milestone, Dr Krishna Ella, Chairman and Managing Director said: "We are proud to announce COVAXIN, India's first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine."

Dr Ella added, "The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform."
Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses.

Speaking about Bharat Biotech's prowess, Suchitra Ella, Joint Managing Director said, "Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic."
"Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India's strength in handling future pandemics," she added.

Bharat Biotech's track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika.